S2Medical (Sweden) Performance
| S2M Stock | SEK 0.01 0.00 0.00% |
The firm has a beta of 0.18, which indicates not very significant fluctuations relative to the market. As returns on the market increase, S2Medical's returns are expected to increase less than the market. However, during the bear market, the loss of holding S2Medical is expected to be smaller as well. At this point, S2Medical AB has a negative expected return of -0.26%. Please make sure to validate S2Medical's treynor ratio and the relationship between the kurtosis and price action indicator , to decide if S2Medical AB performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days S2Medical AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 25.3 M | |
| Total Cashflows From Investing Activities | -3 M | |
| Free Cash Flow | -22.8 M |
S2Medical |
S2Medical Relative Risk vs. Return Landscape
If you would invest 1.20 in S2Medical AB on October 9, 2025 and sell it today you would lose (0.20) from holding S2Medical AB or give up 16.67% of portfolio value over 90 days. S2Medical AB is producing return of less than zero assuming 3.2511% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than S2Medical, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
S2Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for S2Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as S2Medical AB, and traders can use it to determine the average amount a S2Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0788
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | S2M |
Estimated Market Risk
| 3.25 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average S2Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of S2Medical by adding S2Medical to a well-diversified portfolio.
S2Medical Fundamentals Growth
S2Medical Stock prices reflect investors' perceptions of the future prospects and financial health of S2Medical, and S2Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on S2Medical Stock performance.
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Operating Margin | (3.74) % | |||
| Current Valuation | 26.44 M | |||
| Shares Outstanding | 29.37 M | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 3.64 X | |||
| Revenue | 7.7 M | |||
| EBITDA | (18.34 M) | |||
| Cash And Equivalents | 32.15 M | |||
| Cash Per Share | 2.85 X | |||
| Debt To Equity | 5.10 % | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | (19.67 M) | |||
| Earnings Per Share | (1.57) X | |||
| Total Asset | 29.68 M | |||
About S2Medical Performance
Assessing S2Medical's fundamental ratios provides investors with valuable insights into S2Medical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the S2Medical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
S2Medical AB develops, produces, and sells wound healing products for burns and chronic wounds. The company was founded in 2013 and is headquartered in Linkping, Sweden. S2Medical is traded on Stockholm Stock Exchange in Sweden.Things to note about S2Medical AB performance evaluation
Checking the ongoing alerts about S2Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for S2Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| S2Medical AB generated a negative expected return over the last 90 days | |
| S2Medical AB has some characteristics of a very speculative penny stock | |
| S2Medical AB has high historical volatility and very poor performance | |
| S2Medical AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.7 M. Net Loss for the year was (20.08 M) with profit before overhead, payroll, taxes, and interest of 7.42 M. | |
| S2Medical AB has accumulated about 32.15 M in cash with (19.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing S2Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether S2Medical's stock is overvalued or undervalued compared to its peers.
- Examining S2Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating S2Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of S2Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of S2Medical's stock. These opinions can provide insight into S2Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for S2Medical Stock Analysis
When running S2Medical's price analysis, check to measure S2Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy S2Medical is operating at the current time. Most of S2Medical's value examination focuses on studying past and present price action to predict the probability of S2Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move S2Medical's price. Additionally, you may evaluate how the addition of S2Medical to your portfolios can decrease your overall portfolio volatility.